Breaking News Instant updates and real-time market news.

F

Ford

$12.65

0.685 (5.73%)

, GM

General Motors

$36.56

2.0257 (5.87%)

13:03
12/01/16
12/01
13:03
12/01/16
13:03

On The Fly: Top stock stories at midday

The major averages are mixed to kick off December, with the Dow the leader and the Nasdaq the laggard. The last month of the year may have a hard time replicating the strength seen in November as the post-election "Trump rally" that has powered the major averages to new record highs has lost some steam over the last week or so. Providing some optimism, though, is the continued string of good domestic economic data, such as the auto sales and manufacturing reports that were released this morning. ECONOMIC NEWS: In the U.S., initial jobless claims rose 17,000 to 268,000 in the week ended November 26, which was above expectations of 253,000. Markit's manufacturing PMI rose to 54.1 in the final November print, which was higher than the consensus estimate for a reading of 53.9. ISM's manufacturing index rose 1.3 points to 53.2 in November, better than forecast. Construction spending rose 0.5% in October following an unchanged September reading. In Europe, the Eurozone PMI manufacturing index was confirmed at 53.7, the strongest reading for 34 months. Unemployment in the euro zone dropped to 9.8 percent, the lowest level since July 2009. In Asia, China's official manufacturing PMI climbed to 51.7 in November, matching the highest level since 2012, while non-manufacturing PMI climbed to 54.7. COMPANY NEWS: Black Friday weekend discounts helped boost U.S. auto sales for the month of November, with Ford (F) reporting that sales increased 5% and General Motors (GM) saying sales were up 10.2% last month compared to November of last year. Shares of both companies jumped after the announcements, with Ford jumping over 5% and General Motors advancing almost 6%. Also higher after announcing U.S. sales were Fiat Chrysler (FCAU). Meanwhile, Nissan Motor (NSANY), Toyota (TM) and Volkswagen (VLKAY) were all slipping despite announcing increases in their auto sales in the U.S... Caterpillar (CAT) called the Thomson First Call consensus for 2017 of $3.25 earning per share on $38B of sales and revenues "too optimistic considering expected headwinds." Nonetheless, in slides for the company's presentation at the Credit Suisse Industrials Conference, Caterpillar stated that it is on track for over $2B of period and variable cost reduction for the full year of 2016 and that it is "encouraged" by the potential of a U.S. infrastructure bill, tax reform, commodity prices and the recent OPEC announcement. MAJOR MOVERS: Among the notable gainers was bluebird bio (BLUE), which advanced over 17% after reporting interim data from the Phase 1 study of bb2121, its CAR-T treatment candidate for relapsed refractory multiple myeloma. Also higher was Clarcor (CLC), which gained almost 17% after Parker Hannifin (PH) agreed to purchase all of the outstanding shares of the company for $83 per share in cash. Additionally, Skechers (SKX) rose 15% after Buckingham analyst Scott Krasik upgraded the stock to Buy saying the company is one quarter away from a sales inflection driven by a new product cycle and noting that reduced inventory after second quarter reduces the risk of another major negative earnings revision near-term. Among the noteworthy losers was Dollar General (DG), which slid more than 5% after the company reported another disappointing quarter of same-store sales and posted lower than expected earnings. Also lower after earnings was Express (EXPR), which slipped about 21% after the apparel chain slashed its guidance for the year again and offered a bleak outlook for the upcoming holiday season. Additionally, Guess (GES) dropped about 10% after the jeans maker announced disappointing results for the quarter and cut its guidance for the year. INDEXES: Near midday, the Dow was up 51.33, or 0.27%, to 19,174.91, the Nasdaq was down 68.66, or 1.29%, to 5,255.02, and the S&P 500 was down 7.34, or 0.33%, to 2,191.47.

F

Ford

$12.65

0.685 (5.73%)

GM

General Motors

$36.56

2.0257 (5.87%)

FCAU

Fiat Chrysler

$7.70

0.035 (0.46%)

HMC

Honda

$29.71

-0.0263 (-0.09%)

NSANY

Nissan

$18.97

-0.18 (-0.94%)

TM

Toyota

$117.88

-0.65 (-0.55%)

VLKAY

Volkswagen

$27.33

-0.285 (-1.03%)

CAT

Caterpillar

$96.06

0.5 (0.52%)

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

CLC

Clarcor

$82.27

11.815 (16.77%)

PH

Parker-Hannifin

$143.72

4.785 (3.44%)

SKX

Skechers

$26.38

3.595 (15.78%)

DG

Dollar General

$72.95

-4.37 (-5.65%)

EXPR

Express

$10.51

-2.855 (-21.37%)

GES

Guess

$13.80

-1.525 (-9.95%)

  • 01

    Dec

  • 01

    Dec

  • 01

    Dec

  • 01

    Dec

  • 01

    Dec

  • 01

    Dec

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

  • 08

    Dec

  • 19

    Dec

  • 20

    Dec

  • 09

    Jan

  • 10

    Jan

F Ford
$12.65

0.685 (5.73%)

10/31/16
10/31/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ford (F) upgraded to Neutral from Underperform at Daiwa. 2. Chevron (CVX) upgraded to Conviction Buy from Neutral at Goldman with analyst Neil Mehta saying that after a decade of relatively flat production, the company is positioned for "strong volume improvement." 3. Fossil (FOSL) upgraded to Mixed from Negative at OTR Global with the firm saying checks indicate the response to Michael Kors (KORS) watches has been strong. 4. ADTRAN (ADTN) upgraded to Outperform from Market Perform at Northland with analyst Tim Savageaux citing the share pullback over merger concerns of its top customer CenturyLink (CTL). 5. Deere (DE) upgraded to Outperform from Neutral at Baird with analyst Mircea Dobre saying that North American large ag equipment is back to multi-decade lows and there is a sign of demand emerging outside the U.S. and there are meaningful cost savings in the pipeline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/16
BREN
11/22/16
INITIATION
Target $10
BREN
Sell
Ford initiated with a Sell at Berenberg
Target $10.
11/30/16
MACQ
11/30/16
INITIATION
Target $13
MACQ
Neutral
Ford initiated with a Neutral at Macquarie
Macquaire analyst Takuo Katayama initiated Ford with a Neutral and a $13 price target saying the company lacks catalysts over the near-term and its new product flow is underwhelming and expects it to remain that way until late 2018.
12/01/16
12/01/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alcoa (AA) initiated with a Sell at Deutsche Bank. 2. Akorn (AKRX) initiated with a Sell at Goldman. 3. General Motors (GM) initiated with an Outperform at Macquarie, while the firm initiated Fiat Chrysler (FCAU) with an Underperform and Ford (F) with a Neutral. 4. Mobileye (MBLY) initiated with a Buy at Needham. 5. Alarm.com (ALRM) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GM General Motors
$36.56

2.0257 (5.87%)

11/16/16
KEYB
11/16/16
DOWNGRADE
KEYB
Sector Weight
American Axle downgraded on acquisition, headwinds at KeyBanc
As noted earlier, KeyBanc downgraded American Axle (AXL) to Sector Weight from Overweight. Analyst Brett Hoselton says that the company's acquisition of Metaldyne (MPG) does not appear to have accomplished its goals of diversifying its geographic focus and its customer base. Additionally, the analyst expects the company to be hurt by slowing light vehicle production growth in North America and its loss of 25% of the GM (GM) replacement business.
11/22/16
BREN
11/22/16
INITIATION
Target $29
BREN
Sell
General Motors initiated with a Sell at Berenberg
Target $29.
11/30/16
MACQ
11/30/16
INITIATION
Target $44
MACQ
Outperform
General Motors initiated with an Outperform at Macquarie
Macquaire analyst Takuo Katayama initiated General Motors with an Outperform and a $44 price target saying the company will benefit from continued high profitability in North America and earnings growth in China. Katayama prefers GM given its strong product flow thru model year 2019, larger scale to leverage new tech introductions, higher earnings growth from Europe, Cadillac, and GM Financial, and attractive valuation.
FCAU Fiat Chrysler
$7.70

0.035 (0.46%)

11/30/16
MACQ
11/30/16
INITIATION
MACQ
Underperform
Fiat Chrysler initiated with an Underperform at Macquarie
Macquarie analyst Christian Breitsprecher initiated Fiat Chrysler with an Underperform saying it remains strategically the weakest player in key markets of the US and Europe and notes it is currently in a net debt position with a sizable pension liability.
11/22/16
BREN
11/22/16
INITIATION
BREN
Hold
Fiat Chrysler initiated with a Hold at Berenberg
Price target EUR 7.70.
11/28/16
EVER
11/28/16
UPGRADE
EVER
Buy
Fiat Chrysler upgraded to Buy from Sell at Evercore ISI
Evercore ISI analyst George Galliers upgraded Fiat Chrysler to Buy from Sell, making the case that there is "no CEO who gives greater consideration to shareholder value" among those running automakers than Sergio Marchionne. Among the many other reasons he gives for his upgrade, Galliers notes that FCA is not exposed to financial services, and associated credit risk, in the U.S. and he believes it is less exposed to the low-margin and under-pressure passenger car segment. The analyst raised his price target on Fiat Chrysler shares to EUR10 from EUR6.
HMC Honda
$29.71

-0.0263 (-0.09%)

05/27/16
UBSW
05/27/16
DOWNGRADE
UBSW
Sell
Honda downgraded to Sell from Neutral at UBS
09/05/16
GSCO
09/05/16
DOWNGRADE
GSCO
Neutral
Toyota downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Toyota (TM) to Neutral and kept a Buy rating on Honda (HMC).
12/01/16
MACQ
12/01/16
DOWNGRADE
MACQ
Neutral
Honda downgraded to Neutral from Outperform at Macquarie (pre-open)
05/31/16
BOFA
05/31/16
DOWNGRADE
BOFA
Neutral
Honda downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill downgraded Honda to reflect the delayed impact of U.S. mix improvements and the impact from increased strategic spending.
NSANY Nissan
$18.97

-0.18 (-0.94%)

10/05/16
UBSW
10/05/16
DOWNGRADE
UBSW
Neutral
Nissan downgraded to Neutral from Buy at UBS
08/16/16
JPMS
08/16/16
DOWNGRADE
JPMS
Neutral
Nissan downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Akira Kishimoto downgraded Nissan to Neutral on expectations model cycle deterioration in North America will have a large impact. The analyst also upgraded the Japan Auto sector to neutral from bearish.
TM Toyota
$117.88

-0.65 (-0.55%)

05/27/16
UBSW
05/27/16
DOWNGRADE
UBSW
Sell
Toyota downgraded to Sell from Neutral at UBS
05/11/16
MZHO
05/11/16
DOWNGRADE
MZHO
Neutral
Toyota downgraded to Neutral from Buy at Mizuho
08/25/16
SBSH
08/25/16
DOWNGRADE
SBSH
Neutral
Toyota downgraded to Neutral from Buy at Citi
Citi analyst Arifumi Yoshida downgraded Toyota to Neutral citing recent yen strength versus European currencies that will negatively impact the premium Lexus segment.
VLKAY Volkswagen
$27.33

-0.285 (-1.03%)

09/09/16
WELS
09/09/16
NO CHANGE
WELS
Navistar 'making progress' on turnaround, says Wells Fargo
After Navistar reported weaker than expected results but reiterated its full-year guidance, Wells Fargo says that "some" of Navistar's "more severe risks appear to be fading." The firm says that Navistar's deal with Volkswagen (VLKAY) will reduce its liquidity risk, but Wells thinks that Navistar's end market continues to be "weak." The firm raised its price target range on the stock to $17-$20 from $11-$14 but keeps a Market Perform rating on the shares.
09/09/16
GSCO
09/09/16
UPGRADE
Target $20
GSCO
Neutral
Navistar upgraded to Neutral from Sell at Goldman
Goldman Sachs analyst Jerry Revich upgraded Navistar International (NAV) to Neutral saying liquidity risk is "meaningfully reduced" with the capital injection from Volkswagen (VLKAY). Revich raised his price target for the shares to $20 from $2. He believes the near-term risk/reward for the stock is balanced.
11/22/16
GSCO
11/22/16
UPGRADE
GSCO
Buy
Volkswagen upgraded to Buy from Sell at Goldman
Goldman Sachs analyst Stefan Burgstaller double upgraded Volkswagen to Buy from Sell.
11/22/16
BREN
11/22/16
INITIATION
BREN
Sell
Volkswagen reinitiated with a Sell at Berenberg
Price target EUR 98.
CAT Caterpillar
$96.06

0.5 (0.52%)

11/11/16
DBAB
11/11/16
NO CHANGE
Target $102
DBAB
Buy
Deustche says infrastructure upside not fully priced into Machinery names
Deutsche Bank analyst Nicole DeBlase expects infrastructure stimulus to be more of a 2018 "earnings tailwind" with legislation unlikely until the spring of 2017 at the earliest. She's skeptical that the rally in Machinery stocks can continue for an extended amount of time, but feels only 50% of the total benefit has been priced in, to date. Caterpillar (CAT) is the best way to play a U.S. infrastructure stimulus, DeBlase tells investors in a research note. She raised her price target for the shares to $102 from $95. The analyst also raised her price target for Buy-rated Oshkosh (OSK) to $72 from $65, for Hold-rated Deere (DE) to $95 from $90 and for Sell-rated CNH Industrial (CNHI) to $7.20 from $6.24.
11/18/16
OTRG
11/18/16
NO CHANGE
OTRG
Mining Equipment sector upgraded to Positive from Mixed at OTR Global
OTR Global upgraded the Mining Equipment sector to Positive following checks with industry executives that indicate improving conditions for coal and copper miners during the past 90 days driven by an uptick in commodity prices.
12/01/16
DBAB
12/01/16
NO CHANGE
Target $102
DBAB
Buy
Deutsche still sees Caterpillar as top pick after election rally
Deutsche Bank analyst Nicole DeBlase said the Machinery group could be due for a breather following its 12% post-election rally, but she still views Caterpillar as her top pick on a relative basis given her "very high conviction" that EPS is bottoming. The analyst, who sees a combination of restructuring, a recovery in mining and infrastructure stimulus to drive EPS growth in 2017, keeps a $102 price target on Caterpillar shares.
10/11/16
10/11/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Hold from Sell at Evercore ISI with analyst Ken Sena citing the recent pullback in the shares. 2. Tyson Foods (TSN) upgraded to Outperform from Market Perform at BMO Capital with analyst Kenneth Zaslow saying he thinks that the company's "strong underlying fundamentals" should enable its fiscal 2017 profits to beat expectations, and he says that the shares are undervalued. 3. Virgin America (VA) upgraded to Neutral from Underweight at JPMorgan with analyst Jamie Baker saying regulatory approval of the pending Alaska Air (ALK) takeover "remains more likely than not." 4. Cummins (CMI) was upgraded to Conviction Buy from Neutral and Caterpillar (CAT) was upgraded to Buy from Neutral at Goldman. 5. Carbonite (CARB) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Schwartz saying he sees "substantial upside" from current levels due to valuation and fundamentals. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BLUE bluebird bio
$60.35

-4.05 (-6.29%)

12/01/16
BMOC
12/01/16
NO CHANGE
BMOC
bluebird bio data 'impressive,' says BMO Capital
BMO Capital analyst Matthew Luchini says that bluebird bio's Phase I data for its bb2121 product in myeloma was "impressive." The analyst notes that the overall response rate was 78%, and he adds the product to his model for the company ,estimating peak sales of about $3.6B. However, he keeps a Market Perform rating on the shares, citing the approximately 25% increase in the stock in after-hours trading.
12/01/16
PIPR
12/01/16
NO CHANGE
PIPR
Overweight
bluebird bio BCMA CAR-T results early, but encouraging, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer noted that bluebird bio's interim data from its ongoing Phase 1 study of bb2121, the company's investigational anti-BCMA CAR-T candidate in patients with relapsed/refractory multiple myeloma, showed that four of nine patients achieved partial responses and two patients achieved stringent complete responses. While results are early, they are also encouraging, said Schimmer, who has an Overweight rating on bluebird shares.
12/01/16
WELS
12/01/16
NO CHANGE
WELS
bluebird bio data positive, says Wells Fargo
After bluebird bio announced interim Phase 1 dose escalation data for its CAR T product bb2121 in patients with relapsed/refractory multiple myeloma, Wells Fargo says the data shows that the product provides "a profound benefit for patients exhausting available treatment options." Wells thinks that the product could be approved on an accelerated timetable, and it keeps an Outperform rating on the stock.
12/01/16
LEER
12/01/16
NO CHANGE
LEER
Outperform
bluebird bio data looks 'impressive,' says Leerink
Leerink analyst Michael Schmidt notes that bluebird bio (BLUE) announced first clinical data from its ongoing Phase I study of anti-BCMA CAR-T product candidate "bb2121" in relapsed/refractory multiple myeloma, and says it looks 'impressive." While he cautions that the data is still "somewhat immature," the early results justify the high level of excitement around the potential of anti-BCMA CAR-T therapy in relapsed/ refractory myeloma, as several other companies including Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS) have stated plans to also develop anti-BCMA-CART product candidates. Schmidt reiterates an Outperform rating on bluebird bio's shares.
CLC Clarcor
$82.27

11.815 (16.77%)

06/09/16
KING
06/09/16
INITIATION
KING
Neutral
Clarcor reinitiated with a Neutral at CL King
PH Parker-Hannifin
$143.72

4.785 (3.44%)

11/07/16
MSCO
11/07/16
UPGRADE
Target $139
MSCO
Overweight
Parker-Hannifin upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Mili Pothiwala upgraded Parker-Hannifin with an Overweight and a $139 price target citing topline growth, high earnings achievability, and valuation.
11/07/16
EVER
11/07/16
UPGRADE
EVER
Buy
Parker-Hannifin upgraded to Buy from Hold at Evercore ISI
Evercore ISI analyst David Raso upgraded Parker-Hannifin to Buy and raised its price target to $135 from $113 based on lowered expectations, valuation, and and accelerating inflation. The analyst is encouraged by orders turning positive year-over-year in Q3 for the first time in 7 quarters and said Parker is in the sweet spot given its heavy distributor and broad manufacturer presence to any positive swing in industrial inventory stocking patterns.
11/08/16
JPMS
11/08/16
UPGRADE
Target $121
JPMS
Neutral
Parker-Hannifin upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Ann Duignan upgraded Parker-Hannifin to Neutral saying fears of a prolonged decline in U.S. manufacturing have not materialized. The analyst believes 2017 will be a better year for industrial activity following the U.S. elections. She upped her price target for Parker-Hannifin shares to $121 from $117.
11/07/16
11/07/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Time Warner (TWX) upgraded to Outperform from Neutral at Credit Suisse with analyst Omar Sheikh citing attractive valuation. 2. Waste Management (WM) upgraded to Overweight from Equal Weight at Barclays with analyst Jon Windham saying the recent pullback in shares provides a buying opportunity given the company's "strong" underlying fundamentals. 3. Parker-Hannifin (PH) upgraded to Buy from Hold at Evercore ISI and to Overweight from Equal Weight at Morgan Stanley. 4. Biogen (BIIB) upgraded to Overweight from Neutral at Piper Jaffray with analyst Joshua Schimmer saying the company still has time to "get its act together to maximize the value of its SMA franchise, and stop being M&A disciplined/pipeline-undisciplined." 5. Cummins (CMI) upgraded to Buy from Hold at Evercore ISI with analyst David Raso citing lowered expectations, valuation, and accelerating inflation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SKX Skechers
$26.38

3.595 (15.78%)

11/03/16
RILY
11/03/16
DOWNGRADE
RILY
Neutral
Skechers downgraded to Neutral from Buy at B. Riley
11/02/16
WEDB
11/02/16
INITIATION
Target $23
WEDB
Neutral
Skechers initiated with a Neutral at Wedbush
Wedbush analyst Christopher Svezia initiated Skechers with a Neutral and a $23 price target.
12/01/16
BUCK
12/01/16
UPGRADE
Target $31
BUCK
Buy
Skechers upgraded to Buy from Neutral at Buckingham
Buckingham analyst Scott Krasik upgraded Skechers to Buy and raised its price target to $31 from $21 after viewing new products at the FFANY tradeshow. The analyst believes Skechers is one quarter away from a sales inflections driven by a new product cycle and notes reduced inventory after Q2 reduces the risk of another major negative earnings revision near-term. Further, Krasik said Chairman and CEO Robert Greenberg purchased $11M of stock this week, his first purchase in 15 years.
11/03/16
RILY
11/03/16
DOWNGRADE
Target $24
RILY
Neutral
Skechers downgraded to Neutral at B. Riley
As previously reported, B. Riley analyst Jeff Van Sinderen downgraded Skechers to Neutral from Buy, saying his most recent checks only raise his level of concern and he has trouble seeing a catalyst for business reacceleration. The analyst keeps a $24 price target on Skechers shares.
DG Dollar General
$72.95

-4.37 (-5.65%)

10/04/16
CLVD
10/04/16
NO CHANGE
CLVD
Dollar General Q3 comps trending below consensus, says Cleveland Research
Cleveland Research said Dollar General's Q3 are likely trending below consensus driven by continued competitive headwinds. The firm's analyst said Dollar General appears to ramping up promotional/price aggressiveness in order to drive a recovery and sees risk to near-term margin and sales consensus expectations.
10/12/16
KEYB
10/12/16
INITIATION
KEYB
Sector Weight
Dollar General initiated with a Sector Weight at KeyBanc
KeyBanc analyst Bradley Thomas initiated Dollar General with a Sector Weight saying consensus estimates still need to move down and looks to get more positive on further shares weakness.
10/13/16
10/13/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aaron's (AAN) initiated with a Buy at Jefferies. 2. eBay (EBAY) and Etsy (ETSY) coverage assumed with a Neutral at Wedbush. 3. Five Below (FIVE) and Dollar Tree (DLTR) were initiated with an Overweight at KeyBanc while the firm initiated Dollar General (DG) with a Sector Weight. 4. Baxter (BAX) initiated with an Outperform at Wells Fargo. 5. Symantec (SYMC) initiated with an Outperform at FBN Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/25/16
PIPR
11/25/16
NO CHANGE
PIPR
Piper thinks blocking of Overtime Rule came too late
An Obama-appointed judge in Texas surprisingly blocked the Overtime Rule set to take effect on December 1, Piper Jaffray analysts in the Hardlines Retail & Specialty Products space tell investors in a research note. The analysts say that regardless of whether the injunction is upheld, their research suggests that the ruling comes too late for larger companies to pull back on the planned Overtime Rule change. Payroll and IT systems are likely set to adjust this coming Sunday, they point out. Piper's analysts expect the expense headwinds from the OT rule change for retailers/restaurants to remain in place. The retailers they believe that are most impacted from the rule are Dollar General (DG), Dollar Tree (DLTR), Regis (RGS) and Sally Beauty (SBH). The restaurants they believe are most impacted are Bojangles (BOJA), Starbucks (SBUX), Sonic (SONC), Noodles & Company (NDLS), Potbelly (PBPB), Del Taco (TACO) and Zoe's Kitchen (ZOES).
EXPR Express
$10.51

-2.855 (-21.37%)

08/24/16
KING
08/24/16
DOWNGRADE
KING
Neutral
Express downgraded to Neutral from Buy at CL King
08/24/16
WEDB
08/24/16
DOWNGRADE
WEDB
Neutral
Express downgraded to Neutral from Outperform at Wedbush
08/24/16
PIPR
08/24/16
DOWNGRADE
PIPR
Neutral
Express downgraded to Neutral from Overweight at Piper Jaffray
08/25/16
UBSW
08/25/16
DOWNGRADE
Target $10
UBSW
Sell
Express downgraded to Sell from Neutral at UBS
UBS analyst Michael Binetti downgraded Express to Sell and lowered its price target to $10 from $16. The analyst sees downside earnings risk despite the lowered guidance given deteriorating traffic, August traffic trends that he believes are running at the low end, product issues, and potential margin pressure as the company steps up direct mail marketing in 2H 2016.
GES Guess
$13.80

-1.525 (-9.95%)

08/25/16
RILY
08/25/16
UPGRADE
Target $21
RILY
Buy
Guess upgraded to Buy with sale seen as eventual 'end game' at B. Riley
B. Riley analyst Jeff Van Sinderen upgraded Guess to Buy from Neutral following the company's Q2 earnings report and raised his price target on the shares to $21 from $16, noting that the company raised the low end of its earnings guidance for this fiscal year. Van Sinderen believes the "end game" for Guess will be a sale of the company, he tells investors in his post-earnings research note.
08/25/16
PIPR
08/25/16
NO CHANGE
PIPR
Underweight
Piper stays Underweight on Guess after 'other income' drives earnings beat
Piper Jaffray analyst Erinn Murphy reiterates her Underweight rating on Guess despite its better than expected second quarter report, noting that much of its earnings beat came from "other income." While acknowledging the shares will likely rise following the "less worse" than feared results and guidance, Murphy says she is still concerned by the execution risk of adding 55 new stores in Europe and 65 new stores in Asia, the company's heightened inventory compared to its sales and the fact that she thinks management's guidance still seems aggressive. Murphy keeps a $12 price target on Guess shares.
08/25/16
08/25/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Netflix (NFLX) upgraded to Outperform from Market Perform at William Blair with analysts led by Ralph Schackart citing its belief the long term risk/reward is favorable. 2. L-3 Communications (LLL) upgraded to Overweight from Neutral at JPMorgan with analyst Seth Seifman saying L-3's turnaround is already underway but sees further free-cash-flow growth and further valuation upside. 3. Guess (GES) upgraded to Buy from Neutral with analyst Jeff Van Sinderen saying he believes the "end game" for Guess will be a sale of the company. 4. Transocean (RIG) upgraded to Neutral from Sell at Citi with analyst Scott Gruber saying the company has exceeded cost reductions while the backlog remains superior to peers. 5. Primoris (PRIM) upgraded to Buy from Neutral at Seaport Global with analyst Ryan Cassil saying there are fairly low expectations assumed in management's guidance of 90c-$1.10 and the possibility of project starts ahead of management's internal forecast. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/16
07/19/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Super Micro Computer (SMCI) downgraded to Hold from Buy at Stifel and to Neutral from Buy at DA Davidson. DA Davidson downgraded the stock saying the company's miss is its fourth in the last six quarters and its second in a row. The firm is concerned by the deterioration in the company's profitability. 2. Crown Castle (CCI) downgraded to Neutral from Buy at BTIG with the firm citing valuation. 3. Michaels (MIK) downgraded to Neutral from Overweight at JPMorgan with analyst Christopher Horvers saying he views the current valuation as full relative to the company's expected pace of earnings growth. The analyst removed the shares from his firm's Analyst Focus List. 4. Hyatt (H) downgraded to Hold from Buy at Stifel with the firm cited valuation, decelerating U.S. RevPAR, and a lack of catalysts for the lodging sector. 5. Guess (GES) downgraded to Underweight from Neutral at Piper Jaffray with analyst Erinn Murphy saying she's "incrementally wary" on the company's turnaround plan to get to 7.5% in EBIT by 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ABBV

AbbVie

$59.43

0.27 (0.46%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

18:29
12/04/16
12/04
18:29
12/04/16
18:29
Hot Stocks
AbbVie reports five-year IMBRUVICA data, updated RESONATE-2 data »

AbbVie (ABBV) announced…

ABBV

AbbVie

$59.43

0.27 (0.46%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

18:17
12/04/16
12/04
18:17
12/04/16
18:17
Hot Stocks
Celgene, Dana-Farber, U of Arkansas form Myeloma Genome Project »

Celgene, Dana-Farber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

ARQL

ArQule

$1.37

-0.01 (-0.72%)

18:12
12/04/16
12/04
18:12
12/04/16
18:12
Hot Stocks
ArQule reports data presentation on ARQ 092 in sickle cell disease »

ArQule announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$98.50

-0.44 (-0.44%)

, TWX

Time Warner

$93.80

-0.34 (-0.36%)

18:08
12/04/16
12/04
18:08
12/04/16
18:08
Hot Stocks
Box Office Battle: 'Moana,' 'Fantastic Beasts' win post-Thanksgiving weekend »

Disney's (DIS)…

DIS

Disney

$98.50

-0.44 (-0.44%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

VIA

Viacom

$40.35

-1 (-2.42%)

VIAB

Viacom

$36.52

-0.74 (-1.99%)

SNE

Sony

$28.06

-0.16 (-0.57%)

FOX

21st Century Fox

$27.37

-0.71 (-2.53%)

FOXA

21st Century Fox

$27.40

-0.8 (-2.84%)

LGF

Lionsgate

$22.72

0.02 (0.09%)

CMCSA

Comcast

$68.78

-1.08 (-1.55%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.